LUND, Sweden, April 20, 2023 /PRNewswire/ -- Immunovia
(Nasdaq Stockholm: IMMNOV), the diagnostics company that has
launched the world's first test dedicated to the early detection of
pancreatic cancer, today announced it will participate in a webinar
titled "Biomarkers and Liquid Biopsy for Early Detection of
Pancreatic Cancer" hosted by the National Pancreas Foundation on
April 26, 2023, at 7:00 pm ET.
Lara Sucheston-Campbell, Vice President of Clinical and Medical
Affairs at Immunovia, and Dr. Rosario
Ligresti, Director of the Pancreas Center at Hackensack
University Medical Center are scheduled to present as expert
speakers. The 75-minute webinar will provide the latest data,
guidelines, and evidence related to the clinical application of
novel biomarkers and liquid biopsies in the screening of pancreatic
cancer.
The webinar will address how biomarker and liquid biopsy tests
are applied in clinical practice to detect cancer at early stages.
Additionally, the webinar will review the sensitivity, specificity,
and accuracy of tests to detect clinically actionable biomarkers,
the future of early detection in pancreatic cancer, and the impact
on patients.
For more information and to register for the webinar please
click here.
For more information, please contact:
Philipp Mathieu
CEO and President
philipp.mathieu@immunovia.com
Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com
About Immunovia
Immunovia is a diagnostic company with the vision to
revolutionize blood-based diagnostics and increase survival rates
for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test
currently available specifically for the early detection of
pancreatic cancer. The test has unmatched clinical performance.
Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups globally to make this
test available to all high-risk pancreatic cancer groups.
The USA, the first market in
which IMMray™ PanCan-d is commercially available, is the world's
largest market for the detection of pancreatic cancer with an
estimated, addressable market size of 1.8 million individuals per
year who could benefit from our test.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com
The following files are available for download:
|
https://mb.cision.com/Main/13121/3754458/1996931.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.co.uk/news-releases/immunovia-to-participate-in-national-pancreas-foundation-webinar-on-biomarkers-and-liquid-biopsy-for-early-detection-of-pancreatic-cancer-301802726.html